CXCL13 as a Biomarker to Differentiate Sézary Syndrome From Mycosis Fungoides and Other Skin Dis

10 Apr 20264 min read0 viewsJournal Feed

GIST

Sézary syndrome (SS) is a rare and aggressive type of cutaneous T-cell lymphoma (CTCL). Due to its rarity and marked biological heterogeneity, SS diagnosis is frequently delayed, as it requires the integration of multiple complex diagnostic tests interpreted by highly specialized biomedical figures.

In this context, we investigated the expression of CXCL13—increasingly implicated in several inflammatory and neoplastic skin disorders—as a potential screening biomarker to discriminate SS from mycosis fungoides (MF), the most common CTCL subtype, and from clinically overlapping inflammatory skin diseases, i.e. atopic dermatitis (AD), psoriasis (PS) and eczema (EC).

Real-time PCR analysis of CXCL13 mRNA expression in 51 samples showed a significant upregulation in peripheral blood mononuclear cells (PBMCs) from SS patients compared with MF, AD and healthy donors (HD). Protein-level analysis in a larger cohort (n = 142), including allergic and atopic EC patients, revealed significantly higher plasma CXCL13 concentrations in SS than in all other conditions and HD, as assessed by ELISA.

Receiver operating characteristic (ROC) analysis confirmed the excellent performance of plasma CXCL13 as a differential marker (AUC = 93%).

Clinical Editorial

Diagnostic Signal and Study Rationale

The study addresses the challenge of differentiating Sézary syndrome (SS), a rare and aggressive cutaneous T-cell lymphoma, from mycosis fungoides (MF) and other inflammatory skin diseases (atopic dermatitis, psoriasis, eczema) using a candidate blood biomarker, CXCL13.
CXCL13 has been implicated in various inflammatory and neoplastic skin conditions and is evaluated here as a potential screening marker to distinguish SS from MF and inflammatory mimics.

Study Design and Populations

Molecular analysis: real-time PCR assessed CXCL13 mRNA in peripheral blood mononuclear cells (PBMCs) from a cohort of 51 samples.
Protein analysis: plasma CXCL13 quantified by ELISA in a larger cohort (n = 142), including patients with allergic or atopic eczema conditions.
Comparators included MF, atopic dermatitis, psoriasis, eczema, and healthy donors.

Key Findings on CXCL13 Expression

PBMC mRNA: CXCL13 was significantly upregulated in SS patients relative to MF, atopic dermatitis, eczema, and healthy donors.
Plasma protein levels: SS patients exhibited markedly higher plasma CXCL13 concentrations than all other groups, including MF, inflammatory skin diseases, and healthy controls.
Immunohistochemistry: CXCL13 expression in skin biopsies did not provide diagnostic discrimination, as staining was broadly detected across conditions.

Diagnostic Performance and Practical Implications

ROC analysis demonstrated strong discriminative ability of plasma CXCL13 for SS, with an AUC of 93%.
PBMC CXCL13 measurement and plasma CXCL13 assessment via RT-qPCR and ELISA, respectively, were highlighted as practical screening approaches.
The authors suggest these assays could streamline early referral to specialized centers for confirmatory testing and timely initiation of therapy.

Limitations and Context

Immunohistochemical CXCL13 in skin lacked diagnostic specificity, limiting its utility.
The study emphasizes the potential of blood-based CXCL13 quantification but does not provide numbers beyond the abstracted statistical metric (AUC) and qualitative statements.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study

Research Highlights • 22 May 2026

A spatially coordinated keratinocyte–fibroblast circuit recruits MMP9⁺ myeloid cells to drive type I interferon-driven inflammation in photosensitive autoimmunity

Infectious Disease • 24 Apr 2026

Feed Metadata

Source

Frontiers in Immunology